Emerging & Novel Methods
The legal cannabis industry is driving rapid innovation in delivery technology — from pharmaceutical-grade inhalers to cannabis beverages to suppositories. Here's what's available now and what's coming.
Cannabis Beverages
Cannabis-infused beverages are one of the fastest-growing segments in the legal market. Traditional oil-in-water formulations had poor bioavailability and unpredictable onset — similar to edibles. Nanoemulsification technology changed this: by breaking cannabinoids into water-soluble nano-droplets (20–200nm), beverages can now achieve onset in 10–20 minutes with more predictable dose response. Companies like Cann, Keef, and Wunder have built significant markets around low-dose (2–5mg THC) sparkling drinks positioned as alcohol alternatives. Canada has become a testing ground for cannabis beverages — launched as a legal category in 2020. The social drinking occasion is the primary market driver.
Metered-Dose Inhalers (MDIs)
Pharmaceutical-style metered-dose inhalers deliver precise doses of cannabinoid formulation to the lungs — similar to asthma inhalers. Each actuation delivers a consistent, measurable dose (typically 0.5–1mg THC/CBD per puff) without combustion. Companies including Vapen, Aeroinhaler, and several pharmaceutical developers are advancing this technology. MDIs offer the fastest onset of any non-IV method (under 2 minutes), highest reproducibility, and no combustion or thermal degradation. They are particularly promising for medical applications requiring rapid, precise dosing — acute pain, anxiety, breakthrough symptoms. Currently available in limited markets; pharmaceutical-grade versions are in clinical development.
Suppositories
Rectal and vaginal cannabis suppositories have significant legitimate medical applications despite the social stigma. Rectal bioavailability is estimated at 50–70% — substantially higher than oral — and bypasses first-pass metabolism. Onset is 15–30 minutes with 4–8 hour duration. They are primarily used for conditions where other methods are impractical: severe GI disorders that impair oral absorption, post-surgical patients who can't inhale, palliative care patients, and severe nausea/vomiting (when swallowing is impossible). Vaginal suppositories are used specifically for menstrual pain and pelvic inflammatory conditions — with cannabinoids acting locally on uterine and pelvic tissue CB receptors. Multiple medical cannabis companies now offer suppository formulations.
Capsules & Softgels
Cannabis capsules and softgels are the most familiar pharmaceutical format and offer discretion, precise dosing, and convenience. Standard capsules behave like edibles — oil in a gelatin or HPMC shell, absorbed through the GI tract with similar bioavailability (4–20%) and onset (45–120 minutes). Softgels with lipid formulations (typically using MCT or sesame oil as carrier) have improved absorption profiles. Decarboxylated whole-plant extract capsules preserve the entourage effect. Time-release capsule formulations (designed to dissolve at different GI sites) are in development for extended overnight pain relief. For medical patients seeking a pharmaceutical feel without smoking or complex dosing, capsules are the most straightforward option.
What's Coming: The Next Frontier
Several technologies are in active development: Nasal sprays — intranasal delivery bypasses the blood-brain barrier via olfactory pathways, with extremely fast CNS onset (under 2 minutes) and high bioavailability; currently in clinical trials for pain and anxiety. Ocular drops — being researched for glaucoma, where THC's intraocular pressure-reducing effects are well-documented but current topical delivery to the eye is inefficient. Implantable slow-release devices — analogous to hormonal implants, for sustained release over weeks or months for chronic conditions. Personalized formulations — pharmacogenomic testing (CYP2C9, CYP3A4 genotyping) to predict individual metabolism and recommend optimized cannabinoid ratios and doses.
- ✓Nanoemulsion beverages onset: 10–20 min
- ✓MDI inhalers: fastest onset, most precise dosing
- ✓Rectal bioavailability: 50–70%
- ✓Suppositories: onset 15–30 min, duration 4–8 hrs
- ✓Capsules = edibles pharmacokinetically
- ✓Nasal sprays in clinical trials for rapid CNS delivery